Key Points Alto Neuroscience (NYSE:ANRO) reported a net loss of $17.7 million (GAAP) in Q2 2025, with EPS of $(0.65) (GAAP). No revenue was reported, as the company remains in the clinical-stage ...

In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance ...

Lantern Pharma reported a GAAP net loss per share of ($0.40) in Q2 2025, and marking an improvement from ($0.46) per share (GAAP) in Q2 2024. As expected for a clinical-stage biotech, no product ...

The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, ...

Therapeutic advances have altered the neurodegenerative trajectory and improved clinical outcomes for individuals with spinal muscular atrophy. Current therapies increase concentrations of survival ...

Medicine has traditionally relied on a pathophysiology-to-phenotype paradigm, whereby specific pathological processes are linked to signs and symptoms. This paradigm maintains that complex systems are ...